Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism

Trends in Pharmacological Sciences

Volumn 37, Issue 1, 2016, Pages 47-61

  Zhao, Chengguang ^a,b,c   Li, Huameng ^c   Lin, Huey Jen ^d   Yang, Shulin ^a   Lin, Jiayuh ^b   Liang, Guang ^c  

^a NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF DELAWARE   (United States)

Author keywords

activation; cancer; drug resistance; inhibitor; STAT3

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; 5 CHLORO 4 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 2 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO]PYRIMIDINE; ALANTOLACTONE; ANTINEOPLASTIC AGENT; BP 5 087; CELECOXIB; CETUXIMAB; COBIMETINIB; CRYPTOTANSHINONE; CURCUMIN; DEOXYTETRANGOMYCIN; ERLOTINIB; LLL 12; LY 5; NICLOSAMIDE; NIFUROXAZIDE; OPB 31121; OPB 51602; PROTEIN TYROSINE KINASE; PYRIMETHAMINE; S3I 1757; SELUMETINIB; SF 1 066; SH 4 54; SH 5 07; SILIBININ; STAT3 PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; FEEDBACK SYSTEM; GLIOMA; HIGH THROUGHPUT SCREENING; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LYMPHATIC LEUKEMIA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NASOPHARYNX CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DOMAIN; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; ANIMAL; METABOLISM; NEOPLASMS;

ANIMALS; DRUG RESISTANCE, NEOPLASM; FEEDBACK, PHYSIOLOGICAL; HUMANS; NEOPLASMS; STAT3 TRANSCRIPTION FACTOR;

EID: 84951273884     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.10.001     Document Type: Review

References (103)

1. H. Yu, and et al. STATs in cancer inflammation and immunity: a leading role for STAT3 Nat. Rev. Cancer 9 2009 798 809
2. H. Yu, and R. Jove The STATs of cancer - new molecular targets come of age Nat. Rev. Cancer 4 2004 97 105
3. Z. Zhong, and et al. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 Science 264 1994 95 98
4. S. Akira, and et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway Cell 77 1994 63 71
5. M. Spitzner, and et al. STAT3: a novel molecular mediator of resistance to chemoradiotherapy Cancers 6 2014 1986 2011
6. J. Lin, and et al. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3 Oncogene 21 2002 3082 3088
7. H. Song, and et al. Stat3 upregulates MEK5 expression in human breast cancer cells Oncogene 23 2004 8301 8309
8. H. Yu, and et al. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment Nat. Rev. Immunol. 7 2007 41 51
9. J.C. Lieblein, and et al. STAT3 can be activated through paracrine signaling in breast epithelial cells BMC Cancer 8 2008 302
10. J. Lin, and et al. Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells Cancer Res. 62 2002 376 380
11. L. Li, and et al. HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s Clin. Cancer Res. 19 2013 6703 6715
12. H. Yu, and et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions Nat. Rev. Cancer 14 2014 736 746
13. R. Crescenzo, and et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma Cancer Cell 27 2015 516 532
14. M.S. Wake, and C.J. Watson STAT3 the oncogene - still eluding therapy? FEBS J. 282 2015 2600 2611
15. C. Sun, and R. Bernards Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies Trends Biochem. Sci. 39 2014 465 474
16. W. Wei, and et al. The breast cancer susceptibility FGFR2 provides an alternate mode of HER2 activation Oncogene 2015 10.1038/onc.2014.440 Published online February 2, 2015
17. C.M. Blakely, and et al. NF-kappaB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer Cell Rep. 11 2015 98 110
18. C. Sun, and et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma Nature 508 2014 118 122
19. J. Wang, and et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells Oncogene 34 2015 2167 2177
20. M.T. Herrera-Abreu, and et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer Cancer Discov. 3 2013 1058 1071
21. A. Prahallad, and et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100 103
22. M.V. Dieci, and et al. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives Cancer Discov. 3 2013 264 279
23. Editorial Feedback activation of Stat3 is a widespread drug-resistance mechanism Cancer Discov. 4 2014 986
24. H.J. Lee, and et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells Cancer Cell 26 2014 207 221
25. S. Van Schaeybroeck, and et al. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer Cell Rep. 7 2014 1940 1955
26. G.C. Li, and et al. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression Oncotarget 5 2014 8317 8329
27. M. Rokavec, and et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis (vol 124, pg 1853, 2014) J. Clin. Invest. 125 2015 1362
28. A.M. Eiring, and et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia Leukemia 29 2015 586 597
29. C.G. Zhao, and et al. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells Oncotarget 6 2015 14472 14487
30. W. Wen, and et al. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer Mol. Cancer 14 2015 100 111
31. F.Q. Zhang, and et al. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor Oncotarget 6 2015 14329 14343
32. W. Chen, and et al. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma Liver Int. 32 2012 70 77
33. W.H. Liu, and et al. Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cells Oncotarget 6 2015 1750 1768
34. R.J. Chen, and et al. Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells Toxicol. Sci. 115 2010 118 130
35. S. Alas, and B. Bonavida Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis Clin. Cancer Res. 9 2003 316 326
36. Y.Z. Wang, and et al. Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and beta-catenin signaling pathways Oncol. Rep. 26 2011 1173 1180
37. Z.F. Duan, and et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer Clin. Cancer Res. 12 2006 5055 5063
38. Y. Ishii, and et al. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3 Cancer Res. 68 2008 852 860
39. M.S. Redell, and et al. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor Blood 117 2011 5701 5709
40. Z. Duan, and et al. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells Cancer Chemother. Pharmacol. 63 2009 681 689
41. Z. Yang, and et al. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop Oncotarget 6 2015 5072 5087
42. H. Song, and et al. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells Proc. Natl. Acad. Sci. U.S.A. 102 2005 4700 4705
43. C.L. Chen, and et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival Mol. Cancer 7 2008 78
44. K. Miyoshi, and et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor J. Invest. Dermatol. 131 2011 108 117
45. J.S. Park, and et al. STA-21, a promising STAT-3 inhibitor that reciprocally regulates Th17 and Treg Cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis Arthritis Rheumatol. 66 2014 918 929
46. D. Bhasin, and et al. Design, synthesis, and studies of small molecule STAT3 inhibitors Bioorg. Med. Chem. Lett. 18 2008 391 395
47. L. Lin, and et al. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells Neoplasia 12 2010 39 U58
48. L. Lin, and et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells Cancer Res. 71 2011 7226 7237
49. L. Lin, and et al. A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells Int. J. Cancer 130 2012 1459 1469
50. Y. Liu, and et al. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells J. Biol. Chem. 285 2010 27429 27439
51. R. Jain, and et al. Quantitative proteomic analysis of global effect of LLL12 on U87 cell's proteome: an insight into the molecular mechanism of LLL12 J. Proteomics 113 2015 127 142
52. M.X. Zuo, and et al. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy Oncotarget 6 2015 10940 10949
53. H.K. Bid, and et al. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma Clin. Cancer Res. 19 2013 6716 6729
54. W.Y. Yu, and et al. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design J. Med. Chem. 56 2013 4402 4412
55. H. Xiao, and et al. A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells J. Biol. Chem. 290 2015 3418 3429
56. K. Siddiquee, and et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity Proc. Natl. Acad. Sci. U.S.A. 104 2007 7391 7396
57. X.L. Zhang, and et al. A Novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation Cancer Res. 73 2013 1922 1933
58. X.L. Zhang, and et al. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes Biochem. Pharmacol. 79 2010 1398 1409
59. S. Fletcher, and et al. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities Chembiochem 10 2009 1959 1964
60. X.L. Zhang, and et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts Proc. Natl. Acad. Sci. U.S.A. 109 2012 9623 9628
61. D. Resetca, and et al. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization J. Biol. Chem. 289 2014 32538 32547
62. S. Haftchenary, and et al. Potent targeting of the STAT3 protein in brain cancer stem cells: a promising route for treating glioblastoma ACS Med. Chem. Lett. 4 2013 1102 1107
63. P. Yue, and et al. Hydroxamic acid and benzoic acid-based Stat3 inhibitors suppress human glioma and breast cancer phenotypes in vitro and in vivo Cancer Res. 2015 10.1158/0008-5472.CAN-14-3558 Published online June 18, 2015
64. F. Hayakawa, and et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases Blood Cancer J. 3 2013 e166
65. M.J. Kim, and et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells Cancer Lett. 335 2013 145 152
66. M. Ogura, and et al. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies Cancer Sci. 106 2015 896 901
67. A.L. Wong, and et al. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies Ann. Oncol. 26 2015 998 1005
68. L. Brambilla, and et al. Hitting the right spot: mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) Mol. Oncol. 9 2015 1194 1206
69. D.Y. Oh, and et al. Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors Cancer Res. Treat. 2015 10.4143/crt.2014.249 Published online February 26, 2015
70. J.C. Bendell, and et al. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors Cancer Chemother. Pharmacol. 74 2014 125 130
71. T. Okusaka, and et al. Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma Hepatol. Res. 2015 10.1111/hepr.12504 Published online February 11, 2015
72. J. Schust, and et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization Chem. Biol. 13 2006 1235 1242
73. J. Chun, and et al. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells Cancer Lett. 357 2015 393 403
74. D.S. Shin, and et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells Cancer Res. 69 2009 193 202
75. U. Bharadwaj, and et al. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer Oncogene 34 2015 1341 1353
76. J. Bosch-Barrera, and J.A. Menendez Silibinin and STAT3: a natural way of targeting transcription factors for cancer therapy Cancer Treat. Rev. 41 2015 540 546
77. W. Huang, and et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo Oncogene 2015 10.1038/onc.2015.215 Published online June 15, 2015
78. W. Huang, and et al. A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion ACS Chem. Biol. 9 2014 1188 1196
79. C. Zhao, and et al. Promising curcumin-based drug design: mono-carbonyl analogues of curcumin (MACs) Curr. Pharm. Des. 19 2013 2114 2135
80. L. Cen, and et al. New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells BMC Cancer 9 2009 99
81. L. Lin, and et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells Cancer Res. 70 2010 2445 2454
82. Y. Liu, and et al. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells Cell Cycle 9 2010 3423 3427
83. S.L. Fossey, and et al. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines BMC Cancer 11 2011 112
84. M.A. Bill, and et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity Mol. Cancer 9 2010 165
85. L. Lin, and et al. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells Mol. Cancer 9 2010 217
86. K.S. Rath, and et al. HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer Cancer Res. 74 2014 2316 2327
87. K. Selvendiran, and et al. HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase Mol. Cancer Res. 8 2010 1188 1197
88. K. Selvendiran, and et al. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts Mol. Cancer Ther. 9 2010 1169 1179
89. H. Li, and C. Li Multiple ligand simultaneous docking: orchestrated dancing of ligands in binding sites of protein J. Comput. Chem. 31 2010 2014 2022
90. H.M. Li, and et al. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying Celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3) J. Med. Chem. 54 2011 5592 5596
91. Li, H. (2012) Multiple Ligand Simultaneous Docking (MLSD) and Its Applications to Fragment Based Drug Design and Drug Repositioning, PhD Thesis, Ohio State University. Published online at https://etd.ohiolink.edu/
92. Y. Liu, and et al. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells Cancer Prev. Res. 4 2011 1296 1305
93. X.M. Ren, and et al. Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway ACS Med. Chem. Lett. 1 2010 454 459
94. E.A. Nelson, and et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3 Blood 112 2008 5095 5102
95. F. Yang, and et al. Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model Cell Death Dis. 6 2015 e1701
96. H.M. Li, and et al. Drug design targeting protein-protein interactions (PPIs) Using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface J. Med. Chem. 57 2014 632 641
97. A. Takakura, and et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways Hum. Mol. Genet. 20 2011 4143 4154
98. B. Debnath, and et al. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein J. Med. Chem. 55 2012 6645 6668
99. C.R. Chong, and D.J. Sullivan New uses for old drugs Nature 448 2007 645 646
100. S.C. Gupta, and et al. Cancer drug discovery by repurposing: teaching new tricks to old dogs Trends Pharmacol. Sci. 34 2013 508 517
101. E.S. Lander Cutting the Gordian helix - regulating genomic testing in the era of precision medicine N. Engl. J. Med. 372 2015 1185 1186
102. D. Papadatos-Pastos, and et al. Combining targeted therapeutics in the era of precision medicine Br. J. Cancer 112 2015 1 3
103. K. Politi, and R.S. Herbst Lung cancer in the era of precision medicine Clin. Cancer Res. 21 2015 2213 2220